Dose-Tapering Of TNF Inhibitors in Daily Rheumatology Practice Enables the Maintenance of Clinical Efficacy While Improving Cost-Effectiveness
暂无分享,去创建一个
Alej | E. Martı́n-Mola | C. Plasencia | R. Villalba | D. Pascual‐Salcedo | G. Bonilla | Prado Sabina | R. Balsa | A. Martínez-Feito | T. Jurado | L. G. D. Valle | C. Diego
[1] E. Martı́n-Mola,et al. Comparing Tapering Strategy to Standard Dosing Regimen of Tumor Necrosis Factor Inhibitors in Patients with Spondyloarthritis in Low Disease Activity , 2015, The Journal of Rheumatology.
[2] F. Tubach,et al. Step-down strategy of spacing TNF-blocker injections for established rheumatoid arthritis in remission: results of the multicentre non-inferiority randomised open-label controlled trial (STRASS: Spacing of TNF-blocker injections in Rheumatoid ArthritiS Study) , 2015, Annals of the rheumatic diseases.
[3] J. Kremer,et al. Discontinuation of tumour necrosis factor inhibitors in patients with rheumatoid arthritis in low-disease activity: persistent benefits. Data from the Corrona registry. , 2015, Annals of the rheumatic diseases.
[4] J. Bijlsma,et al. Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial , 2015, BMJ : British Medical Journal.
[5] P. Emery,et al. Sustained remission with etanercept tapering in early rheumatoid arthritis. , 2014, The New England journal of medicine.
[6] J. Bijlsma,et al. Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity. , 2014, The Cochrane database of systematic reviews.
[7] M. Nurmohamed,et al. Golimumab trough levels, antidrug antibodies and clinical response in patients with rheumatoid arthritis treated in daily clinical practice , 2014, Annals of the rheumatic diseases.
[8] W. Hung,et al. Significant associations of antidrug antibody levels with serum drug trough levels and therapeutic response of adalimumab and etanercept treatment in rheumatoid arthritis , 2014, Annals of the rheumatic diseases.
[9] W. Dixon,et al. Launch of a checklist for reporting longitudinal observational drug studies in rheumatology: a EULAR extension of STROBE guidelines based on experience from biologics registries , 2013, Annals of the rheumatic diseases.
[10] S. Manganelli,et al. Low doses of etanercept can be effective to maintain remission in ankylosing spondylitis patients , 2013, Clinical Rheumatology.
[11] M. Geijer,et al. Infliximab Dose Reduction Sustains the Clinical Treatment Effect in Active HLAB27 Positive Ankylosing Spondylitis: A Two-Year Pilot Study , 2013, Mediators of inflammation.
[12] M. Dougados,et al. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force , 2013, Annals of the rheumatic diseases.
[13] S. Chandrashekara,et al. Remission in rheumatoid arthritis by different criteria does not converge over the inflammatory markers , 2013, International journal of rheumatic diseases.
[14] M. Weinblatt,et al. Biologic discontinuation studies: a systematic review of methods , 2013, Annals of the rheumatic diseases.
[15] K. Pavelka,et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial , 2013, The Lancet.
[16] P. V. van Riel,et al. Construct and criterion validity of several proposed DAS28-based rheumatoid arthritis flare criteria: an OMERACT cohort validation study , 2012, Annals of the rheumatic diseases.
[17] R. Flipo,et al. Dosage Adjustment of Anti-Tumor Necrosis Factor-α Inhibitor in Ankylosing Spondylitis Is Effective in Maintaining Remission in Clinical Practice , 2012, Journal of Rheumatology.
[18] Giuseppe Turchetti,et al. Systematic literature review on economic implications and pharmacoeconomic issues of rheumatoid arthritis. , 2012, Clinical and experimental rheumatology.
[19] Liliana Dell'Osso,et al. Methodological approach to depressive symptoms in fibromyalgia patients. , 2012, Clinical and experimental rheumatology.
[20] E. Martı́n-Mola,et al. Influence of immunogenicity on the efficacy of longterm treatment of spondyloarthritis with infliximab , 2012, Annals of the rheumatic diseases.
[21] P. V. van Riel,et al. Down-titration and discontinuation of infliximab in rheumatoid arthritis patients with stable low disease activity and stable treatment: an observational cohort study , 2012, Annals of the rheumatic diseases.
[22] B. Hernández-Cruz,et al. Low doses of etanercept can be effective in ankylosing spondylitis patients who achieve remission of the disease , 2011, Clinical Rheumatology.
[23] G Van Assche,et al. Early serial trough and antidrug antibody level measurements predict clinical outcome of infliximab and adalimumab treatment , 2011, Gut.
[24] P. Goupille,et al. Trough Infliximab Concentrations Predict Efficacy and Sustained Control of Disease Activity in Rheumatoid Arthritis , 2010, Therapeutic drug monitoring.
[25] P. Goupille,et al. Infliximab concentration monitoring improves the control of disease activity in rheumatoid arthritis , 2009, Arthritis research & therapy.
[26] M. Dougados,et al. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis , 2008, Annals of the rheumatic diseases.
[27] P. V. van Riel,et al. Sustained effect after lowering high-dose infliximab in patients with rheumatoid arthritis: a prospective dose titration study , 2008, Annals of the rheumatic diseases.
[28] A. Kavanaugh. Economic consequences of established rheumatoid arthritis and its treatment. , 2007, Best practice & research. Clinical rheumatology.
[29] W. Maksymowych,et al. Prospective observational analysis of the efficacy and safety of low-dose (3 mg/kg) infliximab in ankylosing spondylitis: 4-year followup. , 2006, The Journal of rheumatology.
[30] B. Dijkmans,et al. Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis , 2004, Annals of the rheumatic diseases.
[31] P. V. van Riel,et al. Dose titration using the Disease Activity Score (DAS28) in rheumatoid arthritis patients treated with anti-TNF-alpha. , 2002, Rheumatology.
[32] F. Breedveld,et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. , 1998, Arthritis and rheumatism.
[33] F. Arnett. Revised criteria for the classification of rheumatoid arthritis. , 1990, Orthopedic nursing.
[34] M. Liang,et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. , 1988, Arthritis and rheumatism.
[35] A. Cats,et al. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. , 1984, Arthritis and rheumatism.
[36] C. Plasencia,et al. Anti-tnf dose and anti-drug antibody levels in rheumatic and psoriasis patients: Economic repercussion , 2015 .
[37] Giuseppe Turchetti,et al. A systematic literature review of the economic impact of ankylosing spondylitis. , 2012, Clinical and experimental rheumatology.